OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers
Sandra Kang, Bassel F. El‐Rayes, Mehmet Akce
Cancers (2022) Vol. 14, Iss. 7, pp. 1748-1748
Open Access | Times Cited: 24
Sandra Kang, Bassel F. El‐Rayes, Mehmet Akce
Cancers (2022) Vol. 14, Iss. 7, pp. 1748-1748
Open Access | Times Cited: 24
Showing 24 citing articles:
Gallbladder cancer
Juan Carlos Roa, Patricia García, Vinay K. Kapoor, et al.
Nature Reviews Disease Primers (2022) Vol. 8, Iss. 1
Closed Access | Times Cited: 186
Juan Carlos Roa, Patricia García, Vinay K. Kapoor, et al.
Nature Reviews Disease Primers (2022) Vol. 8, Iss. 1
Closed Access | Times Cited: 186
The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
Congqi Shi, Kaiyu Qin, Anqi Lin, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 41
Congqi Shi, Kaiyu Qin, Anqi Lin, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 41
New Challenges in the Management of Cholangiocarcinoma: The Role of Liver Transplantation, Locoregional Therapies, and Systemic Therapy
Ezequiel Mauro, Joana Ferrer, Tamara Saurí, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1244-1244
Open Access | Times Cited: 25
Ezequiel Mauro, Joana Ferrer, Tamara Saurí, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1244-1244
Open Access | Times Cited: 25
Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer
Tianmei Zeng, Guang Yang, Cheng Lou, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 20
Tianmei Zeng, Guang Yang, Cheng Lou, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 20
Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis
Giorgio Frega, Fernando P. Cossío, Jesús M. Bañales, et al.
Cells (2023) Vol. 12, Iss. 16, pp. 2098-2098
Open Access | Times Cited: 19
Giorgio Frega, Fernando P. Cossío, Jesús M. Bañales, et al.
Cells (2023) Vol. 12, Iss. 16, pp. 2098-2098
Open Access | Times Cited: 19
Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies
Xianzhe Yu, Lingling Zhu, Ting Wang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Xianzhe Yu, Lingling Zhu, Ting Wang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Current Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma
Margaret Wheless, Rajiv Agarwal, Laura W. Goff, et al.
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 1, pp. 127-160
Open Access | Times Cited: 7
Margaret Wheless, Rajiv Agarwal, Laura W. Goff, et al.
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 1, pp. 127-160
Open Access | Times Cited: 7
Advances in immunotherapy for biliary tract cancers
Yuhao Zhao, Mao Yang, Jiayi Feng, et al.
Chinese Medical Journal (2023) Vol. 137, Iss. 5, pp. 524-532
Open Access | Times Cited: 14
Yuhao Zhao, Mao Yang, Jiayi Feng, et al.
Chinese Medical Journal (2023) Vol. 137, Iss. 5, pp. 524-532
Open Access | Times Cited: 14
Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review
Wei Zhang, Luo Chu, Zun-Yi Zhang, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 8
Wei Zhang, Luo Chu, Zun-Yi Zhang, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 8
Cholangiocarcinoma in the Era of Immunotherapy
Eleni Manthopoulou, Daryl Ramai, Jahnvi Dhar, et al.
Vaccines (2023) Vol. 11, Iss. 6, pp. 1062-1062
Open Access | Times Cited: 8
Eleni Manthopoulou, Daryl Ramai, Jahnvi Dhar, et al.
Vaccines (2023) Vol. 11, Iss. 6, pp. 1062-1062
Open Access | Times Cited: 8
Targeting Angiogenesis in the Era of Biliary Tract Cancer Immunotherapy: Biological Rationale, Clinical Implications, and Future Research Avenues
Annalisa Schirizzi, G Leonardis, V. Lorusso, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2376-2376
Open Access | Times Cited: 6
Annalisa Schirizzi, G Leonardis, V. Lorusso, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2376-2376
Open Access | Times Cited: 6
PD-1+ T-Cells Correlate with Nerve Fiber Density as a Prognostic Biomarker in Patients with Resected Perihilar Cholangiocarcinoma
Xiuxiang Tan, Jan Bednarsch, Mika Rosin, et al.
Cancers (2022) Vol. 14, Iss. 9, pp. 2190-2190
Open Access | Times Cited: 9
Xiuxiang Tan, Jan Bednarsch, Mika Rosin, et al.
Cancers (2022) Vol. 14, Iss. 9, pp. 2190-2190
Open Access | Times Cited: 9
Durvalumab in Advanced Cholangiocarcinoma: Is Someone Knocking Down the Door?
Angela Dalia Ricci, Rosalba D’Alessandro, Alessandro Rizzo, et al.
Immunotherapy (2023) Vol. 15, Iss. 7, pp. 477-486
Closed Access | Times Cited: 4
Angela Dalia Ricci, Rosalba D’Alessandro, Alessandro Rizzo, et al.
Immunotherapy (2023) Vol. 15, Iss. 7, pp. 477-486
Closed Access | Times Cited: 4
Prognosis of patients with advanced bile tract carcinoma: assessment using the modified-Gustave Roussy Immune Score (mGRIm-s) as a clinico-immunological tool
Yue Ma, Yuting Pan, Yue Li, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 5
Open Access | Times Cited: 1
Yue Ma, Yuting Pan, Yue Li, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 5
Open Access | Times Cited: 1
Hypoxia, Stem Cells and Cancer Stem Cells
Mostafa Manian, Marjan Taherian, Hamid Nickho, et al.
Stem cell biology and regenerative medicine (2024), pp. 29-114
Closed Access | Times Cited: 1
Mostafa Manian, Marjan Taherian, Hamid Nickho, et al.
Stem cell biology and regenerative medicine (2024), pp. 29-114
Closed Access | Times Cited: 1
Analysis of gene expression levels and their impact on survival in 31 cancer-types patients identifies novel prognostic markers and suggests unexplored immunotherapy treatment options in a wide range of malignancies
Claudia Giampietri, Francesca Scatozza, Elena Crecca, et al.
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 6
Claudia Giampietri, Francesca Scatozza, Elena Crecca, et al.
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 6
Efficacy and safety analysis of chemotherapy combined with immunotherapy compared with standard chemotherapy for advanced biliary tract malignant tumors
Zhengfeng Zhang, Dazhen Wang, Yang Liu, et al.
Cancer Medicine (2023) Vol. 12, Iss. 14, pp. 15217-15228
Open Access | Times Cited: 3
Zhengfeng Zhang, Dazhen Wang, Yang Liu, et al.
Cancer Medicine (2023) Vol. 12, Iss. 14, pp. 15217-15228
Open Access | Times Cited: 3
Case Report: Camrelizumab combined with gemcitabine and oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma: a case report and literature review
Zhongyan Zhang, Xin Wang, Hehe Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3
Zhongyan Zhang, Xin Wang, Hehe Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3
Efficacy and Safety of First-Line Targeted Treatment and Immunotherapy for Patients with Biliary Tract Cancer: A Systematic Review and Meta-Analysis
Xin Yan, Huimin Zou, Yunfeng Lai, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 39-39
Open Access | Times Cited: 4
Xin Yan, Huimin Zou, Yunfeng Lai, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 39-39
Open Access | Times Cited: 4
Survival benefit and biomarker of PD‐1 inhibitor combination therapy in first‐line of advanced biliary tract cancer: A retrospective study
Jingyi Guo, Qun Zhou, Mingzhen Zhou, et al.
Cancer Medicine (2023) Vol. 12, Iss. 22, pp. 20699-20711
Open Access | Times Cited: 2
Jingyi Guo, Qun Zhou, Mingzhen Zhou, et al.
Cancer Medicine (2023) Vol. 12, Iss. 22, pp. 20699-20711
Open Access | Times Cited: 2
Immunotherapy
Layal Al Mahmasani, James J. Harding, Ghassan K. Abou‐Alfa
Hematology/Oncology Clinics of North America (2024) Vol. 38, Iss. 3, pp. 643-657
Closed Access
Layal Al Mahmasani, James J. Harding, Ghassan K. Abou‐Alfa
Hematology/Oncology Clinics of North America (2024) Vol. 38, Iss. 3, pp. 643-657
Closed Access
A Systematic Review of the Efficacy of Chemotherapy and Immunotherapy Alone Versus Chemotherapy Combined With Immunotherapy for Biliary Tract Cancer
Gift Andrew Sabola
Research Square (Research Square) (2023)
Open Access
Gift Andrew Sabola
Research Square (Research Square) (2023)
Open Access
An age-group analysis on the efficacy of chemotherapy in older adult patients with metastatic biliary tract cancer: a Japanese cancer registry cohort study
Takeru Hirao, Kenji Ikezawa, Toshitaka Morishima, et al.
BMC Gastroenterology (2023) Vol. 23, Iss. 1
Open Access
Takeru Hirao, Kenji Ikezawa, Toshitaka Morishima, et al.
BMC Gastroenterology (2023) Vol. 23, Iss. 1
Open Access
